Conditions: Non-small Cell Lung Cancer
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 17
Healthy volunteers: no

Brief summary:
This is a Phase II prospective, multicenter study evaluating Progression Free Survival (PFS) after first line treatment with the combination of gemcitabine, docetaxel, and bevacizumab in subjects with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC). PFS will be measured from the date of registration (ie, assignment of subject number when subject meets all entry criteria) to the earliest date of documented evidence of progressive disease, or the date of death due to any cause, whichever occurs first.

Detailed description:

Arms:
arm 1: Single arm treatment with docetaxel, gemcitabine and bevacizumab

Interventions: intervention 1: docetaxel intervention 2: gemcitabine intervention 3: bevacizumab
Intervention descriptions: intervention 1: None intervention 2: None intervention 3: None

Protocol document: